Amentoflavone-loaded nanoparticles enhanced chemotherapy efficacy by inhibition of AKR1B10.

Abstract

Therapeutic nanoparticles can be combined with different anticancer drugs to achieve a synergistic therapy and avoid the limitations of traditional medicine and thus have clinical prospects for cancer. Herein, an effective nanoplatform was developed for self-assembling AMF@DOX-Fe3+-PEG nanoparticles (ADPF NPs) via the coordination of ferric ions (Fe3+), amentoflavone (AMF), doxorubicin (DOX), and PEG-polyphenol. The ADPF NPs possessed high drug loading efficiency, good stability and dispersion in water, prolonged blood circulation, and pH-dependent release, which leading to targeted drug transport and enhanced drug accumulation in the tumor. The AMF from the ADPF NPs could inhibit the expression of the Aldo-keto reductase family 1B10 (AKR1B10) and nuclear factor-kappa B p65 (NF-κB p65), which reduced the cardiotoxicity induced by DOX and enhanced the chemotherapy efficacy. This study established a new strategy of combining drug therapy with a nanoplatform. This new strategy has a wide application prospect in clinical tumor therapy.

• Authors: Fang Zhao, Yumei Qian, Hongxia Li, Yang Yang, Jing Wang, Weixiong Yu, Min Li, Wei Cheng, Lingling Shan
• Journal: Nanotechnology (Nanotechnology) Vol. 33 Issue 38 (Jun 28 2022) ISSN: 1361-6528 [Electronic] England
• PMID: 35697009 (Publication Type: Journal Article)
• Copyright: Creative Commons Attribution license.

Chemical References

• Biflavonoids
• Doxorubicin
• amentoflavone
• Aldo-Keto Reductases

Topics

• Aldo-Keto Reductases
• Biflavonoids
• Cell Line, Tumor
• Doxorubicin (pharmacology, therapeutic use)
• Nanoparticles (therapeutic use)